将免疫检查点抑制剂纳入上皮性卵巢癌治疗
本系统综述纳入7项III期随机试验共5671例上皮性卵巢癌患者,评估免疫检查点抑制剂(CPI)在新诊断和复发患者中的疗效。单药PD-L1抑制剂在新诊断卵巢癌中未显示显著疗效;贝伐珠单抗+奥拉帕利+度伐利尤单抗三药维持治疗在无肿瘤BRCA突变患者中较贝伐珠单抗单药维持延长无进展生存期;CPI在铂敏感和铂耐药复发卵巢癌中均无效。
要点
- 单药PD-L1抑制剂在新诊断上皮性卵巢癌中未显示显著疗效。
- 无肿瘤BRCA突变患者中,贝伐珠单抗+奥拉帕利+度伐利尤单抗三药维持较贝伐珠单抗单药维持无进展生存期更长。
- CPI在铂敏感(n=1031)和铂耐药(n=1420)复发上皮性卵巢癌中均无效。
核心结论
- 在标准治疗(含PARP抑制剂,联合或不联合贝伐珠单抗)基础上加用CPI的价值仍不明确,正在进行的临床试验正在评估。
- CTLA-4与PD-1抑制剂联合可能增强上皮性卵巢癌免疫治疗疗效,相关研究正在进行。
研究设计与样本
- 系统综述,纳入7项评估CPI在上皮性卵巢癌中作用的III期随机试验,其中新诊断3项、复发4项,共包含5671例患者数据。
- PROSPERO注册号:CRD42024536017。
主要发现
- 单药PD-L1抑制剂试验在新诊断卵巢癌中未显示显著疗效。
- 无肿瘤BRCA突变患者中,贝伐珠单抗+奥拉帕利+度伐利尤单抗三药维持治疗较贝伐珠单抗单药维持治疗与更长的无进展生存期相关。
- CPI在铂敏感复发上皮性卵巢癌(n=1031)中无效。
- CPI在铂耐药复发上皮性卵巢癌(n=1420)中无效。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Therapeutic interventions for epithelial ovarian cancer (EOC) have increased greatly over the last decade but improvements outside of biomarker selected therapies have been limited. There remains a pressing need for more effective treatment options that can prolong survival and enhance the quality of life of patients with EOC. In contrast to the significant benefits of immunotherapy with immune checkpoint inhibitors (CPI) seen in many solid tumors, initial experience in EOC suggests limited efficacy of CPIs monotherapy. METHODS: A systematic review of phase III studies testing the role of CPIs in ovarian cancer was performed. RESULTS: Seven randomized trials testing CPIs in newly diagnosed (n = 3) and recurrent (n = 4) EOC are evaluated. Overall, those trials included data of 5671 patients. Single-agent PD-L1 inhibitor trials have not shown significant efficacy in newly diagnosed ovarian cancer. Triplet maintenance with bevacizumab plus olaparib and durvalumab is associated with longer progression-free survival than maintenance with bevacizumab alone in patients without tumor BRCA mutations. CPIs were not effective in platinum-sensitive (n = 1031) and platinum-resistant (n = 1420) EOC. CONCLUSIONS: The value of adding CPI to standard treatment including poly (ADP-ribose) polymerase (PARP) inhibitors with or without bevacizumab remains unclear and is being addressed in ongoing clinical trials. The combination of cytotoxic T-lymphocyte associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) inhibitors may enhance the efficacy of immunotherapy in EOC and studies are underway to investigate the combination of CPI with other emerging treatment modalities. PROSPERO registration ID: CRD42024536017.
引用
- Bogani G, Moore KN, Ray-Coquard I, et al. Incorporating immune checkpoint inhibitors in epithelial ovarian cancer. Gynecol Oncol. 2025. PMID: 39764856. doi:10.1016/j.ygyno.2024.12.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。